PriceTargets.com logo

Inhibrx Biosciences - INBX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $197.50
  • Forecasted Upside: 94.07%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$101.77 As of 09/16/2026 05:00 PM ET
▼ -3.84 (-3.64%)

This chart shows the closing price for INBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inhibrx Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INBX

Analyst Price Target is $197.50
▲ +94.07% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Inhibrx Biosciences in the last 3 months. The average price target is $197.50, with a high forecast of $245.00 and a low forecast of $150.00. The average price target represents a 94.07% upside from the last price of $101.77.

This chart shows the closing price for INBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in Inhibrx Biosciences. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026
  • 1 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/18/2026
  • 1 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/17/2026
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/16/2026

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/11/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/27/2026CitigroupReiterated RatingMarket Perform ➝ Market Perform
8/24/2026HC WainwrightInitiated CoverageBuy$245.00
6/16/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/24/2026Lifesci CapitalUpgradeStrong-Buy
4/9/2026Zacks ResearchUpgradeHold
4/8/2026Stifel NicolausInitiated CoverageBuy$150.00
1/22/2026Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/19/2025CitigroupReiterated RatingMarket Perform ➝ Market Perform
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
8/22/2025Citizens JmpReiterated RatingMarket Perform ➝ Market Perform
5/15/2025Citizens JmpReiterated RatingMarket Perform ➝ Market Perform
1/22/2025Citizens JmpReiterated RatingMarket Perform ➝ Market Perform
7/23/2024Citizens JmpInitiated CoverageMarket Perform
1/23/2024Lifesci CapitalDowngradeOutperform ➝ Market Perform
1/23/2024Citizens JmpReiterated RatingOutperform ➝ Market Perform
11/20/2023Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$27.00
8/23/2023Citizens JmpLower TargetOutperform ➝ Outperform$35.00 ➝ $27.00
8/8/2023Lifesci CapitalReiterated RatingOutperform
4/26/2023Lifesci CapitalReiterated RatingOutperform
3/8/2023Citizens JmpLower TargetMarket Outperform$40.00 ➝ $35.00
3/7/2023Credit Suisse GroupReiterated RatingOutperform$46.00
11/8/2022Credit Suisse GroupLower TargetOutperform$48.00 ➝ $46.00
10/5/2022Citizens JmpReiterated RatingBuy$40.00
10/5/2022EvercoreBoost TargetOutperform$54.00 ➝ $60.00
8/15/2022Credit Suisse GroupLower Target$48.00
8/9/2022Credit Suisse GroupLower TargetOutperform$53.00 ➝ $48.00
7/6/2022Citizens JmpReiterated RatingBuy$40.00
6/6/2022Citizens JmpReiterated RatingBuy$40.00
4/11/2022Citizens JmpReiterated RatingBuy$40.00
3/16/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$40.00
3/2/2022Citizens JmpLower TargetMarket Outperform$53.00 ➝ $40.00
1/5/2022Citizens JmpReiterated RatingBuy$53.00
11/10/2021Credit Suisse GroupBoost TargetOutperform$44.00 ➝ $53.00
11/2/2021Citizens JmpBoost TargetOutperform$46.00 ➝ $53.00
10/13/2021Citizens JmpReiterated RatingBuy$46.00
9/21/2021Citizens JmpInitiated CoverageBuy$46.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

1.18 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 26 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 26 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Inhibrx Biosciences logo
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $101.77
Low: $99.06
High: $106.44

50 Day Range

MA: $99.40
Low: $79.25
High: $126.70

52 Week Range

Now: $101.77
Low: $26.19
High: $155.29

Volume

363,483 shs

Average Volume

320,755 shs

Market Capitalization

$1.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Inhibrx Biosciences?

The following Wall Street research analysts have issued reports on Inhibrx Biosciences in the last twelve months: Citigroup Inc., HC Wainwright, Lifesci Capital, Stifel Nicolaus, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for INBX.

What is the current price target for Inhibrx Biosciences?

0 Wall Street analysts have set twelve-month price targets for Inhibrx Biosciences in the last year. Their average twelve-month price target is $197.50, suggesting a possible upside of 93.6%. HC Wainwright has the highest price target set, predicting INBX will reach $245.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $150.00 for Inhibrx Biosciences in the next year.
View the latest price targets for INBX.

What is the current consensus analyst rating for Inhibrx Biosciences?

Inhibrx Biosciences currently has 1 sell rating, 2 hold ratings, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for INBX.

What other companies compete with Inhibrx Biosciences?

Other companies that are similar to Inhibrx Biosciences include Oruka Therapeutics, Scholar Rock, Mirum Pharmaceuticals, Travere Therapeutics and Kiniksa Pharmaceuticals International. Learn More about companies similar to Inhibrx Biosciences.

How do I contact Inhibrx Biosciences' investor relations team?

Inhibrx Biosciences' physical mailing address is 11025 N. Torrey Pines Road, Suite 140, LA Jolla, CA, 92037. The company's listed phone number is 858-795-4220 and its investor relations email address is [email protected]. The official website for Inhibrx Biosciences is www.inhibrx.com. Learn More about contacing Inhibrx Biosciences investor relations.